BioNTech & United States — Food and Drug Administration
3 shared events · Importance 3 · Last updated Apr 11, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Business
BioNTech: BioNTech, in collaboration with Pfizer, halted a large U.S. trial for their updated COVID-19 vaccine due to low enrollment, potentially impacting future approvals and market share for the 50-64 age group.
Apr 01, 2026 · 6 articles
Tech
BioNTech: BioNTech announced positive Phase 2 clinical trial results for trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, in patients with endometrial cancer. This positive development could lead to a biologics license application in 2026 and further clinical trials, potentially increasing its market value and product pipeline.
Apr 11, 2026 · 7 articles
Tech
BioNTech: BioNTech is collaborating with Boehringer Ingelheim to evaluate a novel immuno-oncology combination in ES-SCLC. BioNTech will supply pumitamig and retains full rights to its asset.
Apr 09, 2026 · 6 articles
NEWSDESK
Explore this relationship live
Track how BioNTech and United States — Food and Drug Administration interact across events, view sentiment trends, and discover connected entities.
Open Dashboard